Loading clinical trials...
Loading clinical trials...
A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)
Conditions
Interventions
Visugromab
Matching placebo for visugromab
+3 more
Locations
25
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
Duke University Medical Center
Durham, North Carolina, United States
Thorax Clinic Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
University Hospital Würzburg
Würzburg, Bavaria, Germany
Start Date
August 1, 2025
Primary Completion Date
March 31, 2029
Completion Date
March 31, 2031
Last Updated
February 27, 2026
NCT06403436
NCT01137825
NCT06311721
NCT06059547
NCT02293954
NCT00483366
Lead Sponsor
CatalYm GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions